A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults

AIDS ◽  
2022 ◽  
Vol 36 (2) ◽  
pp. 319-321
Author(s):  
Christine Durier ◽  
Séverine Mercier-Delarue ◽  
Nathalie Colin De Verdière ◽  
Vincent Meiffrédy ◽  
Sophie Matheron ◽  
...  
Keyword(s):  
Immune Response ◽  
Yellow Fever ◽  
Yellow Fever Vaccine

scholarly journals A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine

2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Carla R. B. Bonin ◽  
Guilherme C. Fernandes ◽  
Rodrigo W. dos Santos ◽  
Marcelo Lobosco
Keyword(s):  
Immune Response ◽  
Computational Model ◽  
Yellow Fever ◽  
Yellow Fever Vaccine

scholarly journals Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice

Virology ◽  
2014 ◽  
Vol 468-470 ◽  
pp. 28-35 ◽  
Author(s):  
Irina Tretyakova ◽  
Brian Nickols ◽  
Rachmat Hidajat ◽  
Jenny Jokinen ◽  
Igor S. Lukashevich ◽  
...  
Keyword(s):  
Immune Response ◽  
Yellow Fever ◽  
Plasmid Dna ◽  
Specific Immune Response ◽  
Yellow Fever Vaccine

scholarly journals Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda

2019 ◽  
Vol 4 ◽  
pp. 182 ◽  
Author(s):  
Derick Kimathi ◽  
Aitana Juan ◽  
Philip Bejon ◽  
Rebecca F. Grais ◽  
George M. Warimwe ◽  
...  
Keyword(s):  
Immune Response ◽  
Randomized Controlled Trials ◽  
Yellow Fever ◽  
Vaccine Dose ◽  
World Health ◽  
Yellow Fever Vaccine ◽  
Controlled Trials ◽  
Post Vaccination ◽  
Randomized Controlled ◽  
Link Type

Introduction: Yellow fever is endemic in specific regions of sub-Saharan Africa and the Americas, with recent epidemics occurring on both continents. The yellow fever vaccine is effective, affordable and safe, providing life-long immunity following a single dose vaccination. However, the vaccine production process is slow and cannot be readily scaled up during epidemics. This has led the World Health Organization (WHO) to recommend the use of fractional doses as a dose-sparing strategy during epidemics, but there are no randomized controlled trials of fractional yellow fever vaccine doses in Africa. Methods and analysis: We will recruit healthy adult volunteers, adults living with HIV, and children to a series of randomized controlled trials aiming to determine the immunogenicity and safety of fractional vaccine doses in comparison to the standard vaccine dose. The trials will be conducted across two sites; Kilifi, Kenya and Mbarara, Uganda. Recruited participants will be randomized to receive fractional or standard doses of yellow fever vaccine. Scheduled visits will include blood collection for serum and peripheral blood mononuclear cells (PBMCs) before vaccination and on various days – up to 2 years – post-vaccination. The primary outcome is the rate of seroconversion as measured by the plaque reduction neutralization test (PRNT50) at 28 days post-vaccination. Secondary outcomes include antibody titre changes, longevity of the immune response, safety assessment using clinical data, the nature and magnitude of the cellular immune response and post-vaccination control of viremia by vaccine dose. Ethics and dissemination: The clinical trial protocols have received approval from the relevant institutional ethics and regulatory review committees in Kenya and Uganda, and the WHO Ethics Review Committee. The research findings will be disseminated through open-access publications and presented at relevant conferences and workshops. Registration: ClinicalTrials.gov NCT02991495 (registered on 13 December 2016) and NCT04059471 (registered on 15 August 2019).

scholarly journals Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

2008 ◽  
Vol 205 (13) ◽  
pp. 3119-3131 ◽  
Author(s):  
Denis Gaucher ◽  
René Therrien ◽  
Nadia Kettaf ◽  
Bastian R. Angermann ◽  
Geneviève Boucher ◽  
...  
Keyword(s):  
Immune Response ◽  
Transcription Factors ◽  
Immune Responses ◽  
Yellow Fever ◽  
Cell Response ◽  
T Cell Response ◽  
Yellow Fever Vaccine ◽  
Effector Cells ◽  
Polychromatic Flow Cytometry

Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.

CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles

Vaccine ◽  
2017 ◽  
Vol 35 (45) ◽  
pp. 6166-6171 ◽  
Author(s):  
Catherine Goujon ◽  
Marie-Lise Gougeon ◽  
Laura Tondeur ◽  
Béatrice Poirier ◽  
Valérie Seffer ◽  
...  
Keyword(s):  
Immune Response ◽  
Yellow Fever ◽  
Yellow Fever Vaccine

scholarly journals Intradermally Administered Yellow Fever Vaccine at Reduced Dose Induces a Protective Immune Response: A Randomized Controlled Non-Inferiority Trial

PLoS ONE ◽  
2008 ◽  
Vol 3 (4) ◽  
pp. e1993 ◽  
Author(s):  
Anna H. Roukens ◽  
Ann C. Vossen ◽  
Peter J. Bredenbeek ◽  
Jaap T. van Dissel ◽  
Leo G. Visser
Keyword(s):  
Immune Response ◽  
Yellow Fever ◽  
Protective Immune Response ◽  
Yellow Fever Vaccine ◽  
Reduced Dose ◽  
Randomized Controlled

scholarly journals Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals

2020 ◽  
Vol 21 (S17) ◽  
Author(s):  
Carla Rezende Barbosa Bonin ◽  
◽  
Guilherme Côrtes Fernandes ◽  
Reinaldo de Menezes Martins ◽  
Luiz Antonio Bastos Camacho ◽  
...  
Keyword(s):  
Immune Response ◽  
Yellow Fever ◽  
Booster Dose ◽  
Plasma Cells ◽  
Primary Vaccination ◽  
Yellow Fever Vaccine ◽  
Open Questions ◽  
Human Immune Response ◽  
Adults And Children ◽  
Using Data

Abstract Background An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions. Results This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature. Conclusions Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF.

Sign in / Sign up

Export Citation Format

Share Document